Frankfurt
08.09.25 | 08:11
0,059 Euro
-0,84 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 67 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07. | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 119 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 12.06. | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | 162 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen | |
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.06.2025 | 266 | Xetra Newsboard | Das Instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 12.06.2025 The instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.06. | Isofol Medical AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025 | 130 | GlobeNewswire (Europe) | GOTHENBURG, 11 June 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at which the following main resolutions were passed by the shareholders.
The... ► Artikel lesen | |
| 05.06. | Isofol Medical AB: Isofol announces final terms of the rights issue and the potential overallotment issue | 121 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 5 June 2025 - The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol" or the "Company") announced on 12 May 2025, that the Board of Directors, subject... ► Artikel lesen | |
| 21.05. | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | 111 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen | |
| 03.04. | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | 349 | Edison Investment Research | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen | |
| 19.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | 94 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen | |
| 12.11.24 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | 210 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen | |
| 17.09.24 | Isofol Medical AB: Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin | 400 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 17, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,596 | +0,45 % | INSIDERALARM bei Evotec! Valneva mit neuem KURSZIEL! Vidac Pharma Aktie bald mit neuem ALLZEITHOCH? | Endlich! Bei Evotec sorgen Insider für ein wichtiges Signal. Die Aktie reagiert zwar noch nicht, aber mittelfristig könnte sich dies als Kaufsignal herausstellen. Derzeit herrscht noch Skepsis. Bullish... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,260 | +1,94 % | Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia | ||
| CARDIOL THERAPEUTICS | 0,948 | +6,64 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,085 | +1,65 % | PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq | ||
| CENTOGENE | 0,120 | +9,09 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 3,902 | +1,43 % | Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics | ||
| BIOMERIEUX | 114,70 | +0,70 % | BIOMERIEUX: bioMérieux - First-Half 2025 Results | ||
| CYCLACEL | 6,129 | -4,53 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 29,600 | 0,00 % | Genus - Additional Listing | ||
| ANAPTYSBIO | 18,500 | -2,12 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update | Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial;... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,975 | -4,41 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 3,420 | +8,06 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| AKESO | 15,100 | -1,31 % | Akeso, Inc.: Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy | HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,059 Euro und damit -0,84 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.